Skip to main content

Table 4 Comparison of nephrotoxicity during cisplatin-based chemotherapy

From: A comparison of nephrotoxicity between patients with a solitary-functioning kidney and those with bilateral-functioning kidneys in cisplatin-based chemotherapy for advanced urothelial carcinoma: a Japanese retrospective multi-institutional study

  All patients Pretreatment eGFR
≥60 mL/min/1.73m2
Pretreatment eGFR
< 60 mL/min/1.73m2
Course % Baseline eGFR
impairment
Pretreatment eGFR
≥60 mL/min/1.73m2
(n = 119)
impaird patient /n (%)
Pretreatment eGFR
< 60 mL/min/1.73 m2 (n = 125)
impaird patient /n (%)
p Bilateral functioning
kidneys (n = 83)
impaird patient /n (%)
Solitary functioning kidney (n = 36)
impaird patient /n (%)
p Bilateral functioning kidneys (n = 45)
impaird patient /n (%)
Solitary functioning kidney
impaird patient /n (%)
p
post 1st course >  10% impairment 38/119 (31.9%) 23/125 (18.4%) 0.015 28/83 (33.7%) 10/36 (27.7%) 0.52 9/45 (20.0%) 15/80 (18.7%) 0.73
>  20% impairment 19/119 (15.9%) 10/125 (8.0%) 0.054 15/83 (18.0%) 4/36 (11.1%) 0.34 6/45 (13.3%) 5/80 (6.2%) 0.17
>  30% impairment 4/119 (3.4%) 4/125 (3.2%) 0.94 3/83 (3.6%) 1/36 (2.7%) 0.81 3/45 (6.6%) 2/80 (2.5%) 0.098
post 2nd course >  10% impairment 29/104 (27.8%) 17/110 (14.5%) 0.026 20/72 (27.7%) 9/32 (28.1%) 0.97 10/42 (23.8%) 7/68 (10.2%) 0.056
>  20% impairment 13/104 (12.5%) 6/110 (5.4%) 0.070 9/72 (12.5%) 4/32 (12.5%) 1.00 4/42 (9.5%) 2/68 (2.9%) 0.14
>  30% impairment 6/104 (5.8%) 3/110 (2.7%) 0.26 4/72 (5.5%) 2/32 (6.2%) 0.88 2/42 (4.7%) 1/68 (1.4%) 0.30
post 3rd course >  10% impairment 29/78 (37.2%) 15/82 (18.3%) 0.011 17/54 (31.4%) 12/27 (44.4%) 0.25 8/24 (33.3%) 7/58 (12.1%) 0.023
>  20% impairment 18/78 (23.0%) 7/82 (8.5%) 0.015 14/54 (25.9%) 4/27 (14.8%) < 0.001 4/24 (16.6%) 3/58 (5.2%) 0.091
>  30% impairment 5/78 (6.4%) 2/82 (2.4%) 0.23 2/54 (3.7%) 3/27 (11.1%) 0.19 2/24 (8.3%) 0/58 (0.0%) 0.026
post 4th course >  10% impairment 26/59 (44.1%) 13/59 (22.0%) 0.010 17/39 (43.6%) 9/20 (45.0%) 0.91 4/20 (20.0%) 9/39 (23.0%) 0.78
>  20% impairment 12/59 (20.3%) 3/59 (5.1%) 0.028 9/39 (23.0%) 3/20 (15.0%) 0.46 2/20 (10.0%) 1/39 (2.5%) 0.21
>  30% impairment 7/59 (11.9%) 1/59 (1.7%) 0.012 5/39 (12.8%) 2/20 (10.0%) 0.75 1/20 (5.0%) 0/39 (0.0%) 0.16
during all courses >  10% impairment 56/119 (47.1%) 32/125 (25.6%) < 0.001 39/83 (46.9%) 17/36 (47.2%) 0.98 16/45 (33.3%) 18/80 (22.5%) 0.14
>  20% impairment 25/119 (21.0%) 17/125 (13.6%) 0.125 18/83 (21.6%) 7/36 (19.4%) 0.78 10/45 (22.2%) 7/80 (8.7%) 0.034
>  30% impairment 16/119 (13.4%) 7/125 (5.6%) 0.036 11/83 (13.2%) 5/36 (13.8%) 0.92 5/45 (11.1%) 3/80 (3.8%) 0.11
\